ArticleJournal of arrhythmia2021
Safety and efficacy of cryoballoon ablation for the treatment of paroxysmal and persistent AF in a real-world global setting: Results from the Cryo AF Global Registry.
Article in Journal of arrhythmia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- The Cost Utility of Rhythm Control Treatment Sequences in Patients with Atrial Fibrillation: Anti-arrhythmic Drugs Versus Catheter Ablation.PharmacoEconomics · 2026Article
- Association of epicardial fat volume with early outcomes in patients undergoing cryoablation for atrial fibrillation.BMC cardiovascular disorders · 2026Article
- Comparative Outcomes of Deep Sedation Versus General Anesthesia in Cryoablation for Atrial Fibrillation: Insights From the Korean Heart Rhythm Society Cryoablation Registry.Korean circulation journal · 2026Article
- Cryoballoon Ablation for Persistent Atrial Fibrillation in Japan: Cryo Global Registry 12-Months Results.Journal of arrhythmia · 2026Article
- Adjunctive empirical superior vena cava isolation with fourth-generation cryoballoon in paroxysmal atrial fibrillation does not improve outcomes and increases complications: the randomized CISPAF trial.Frontiers in cardiovascular medicine · 2026Article
- Real-world experience with the pentaspline pulsed field ablation system: one-year outcomes of the FARADISE registry.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Observational
- Pulsed-Field Ablation for Persistent Atrial Fibrillation in EU-PORIA Registry.Journal of cardiovascular electrophysiology · 2025Article
- Predictors of Arrhythmia Recurrence After Cryoballoon Ablation for Persistent Atrial Fibrillation: A Sub-Analysis of the Cryo Global Registry.Journal of cardiovascular electrophysiology · 2025Article
- Impact of atrial fibrillation diagnosis-to-ablation time on 24-month efficacy and safety outcomes in the Cryo Global Registry.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Observational
- Real-world sex differences in healthcare utilization after cryoballoon ablation: 2-year outcomes from the Cryo Global Registry.Frontiers in cardiovascular medicine · 2025Article
- Transseptal Puncture and Cryoballoon Ablation of Atrial Fibrillation in Patients with Atrial Septal Occluder or Atrial Septal Defect Surgical Repair: A Single Center Experience.Anatolian journal of cardiology · 2024Article
- Long-term Outcome of Cryoballoon Ablation in Korean Patients With Atrial Fibrillation: Real-World Experience From the Cryo Global Registry.Korean circulation journal · 2024Article
- Will Cryoballoon Ablation Cool Down Atrial Fibrillation in Korea?Korean circulation journal · 2024Article
- Pulsed field ablation and cryoballoon ablation for pulmonary vein isolation: insights on efficacy, safety and cardiac function.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2024Article
- Regional variations in patient selection and procedural characteristics for cryoballoon ablation of atrial fibrillation in the cryo global registry.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2024Article
- Electrophysiology lab efficiency using cryoballoon for pulmonary vein isolation in central and eastern Europe: A sub-analysis of the cryo global registry study.Cardiology journal · 2024Article
- Atrial Fibrillation Ablation: Current Practice and Future Perspectives.Journal of clinical medicine · 2023Review
- Atrial fibrillation cryoablation is an effective day case treatment: the UK PolarX vs. Arctic Front Advance experience.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023Article
- Adverse events in cryoballoon ablation for pulmonary vein isolation: Insight from the Food and Drug Administration Manufacturer and User Facility Device Experience.Journal of arrhythmia · 2023Article
- Safety of the Radiofrequency Balloon for Pulmonary Vein Isolation: A Focus on Lesion Metric Analysis of Posterior Electrodes.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCryoballoon ablation is a commonly used approach to treat patients with atrial fibrillation (AF).
objectivesReport on the safety and efficacy of cryoballoon ablation for the treatment of AF in the largest global cohort of cryoablated patients prospectively studied within a single registry.
methodsThe
resultsDuring this evaluation window, 2922 subjects completed an index cryoballoon procedure, and 1440 completed 12 month follow-up. The cohort was 61 ± 12 years of age, 36.3% female, and 78.7% PAF. Serious device- and procedure-related adverse event rates were 1.5% and 3.4%, respectively. Freedom from AF/AFL/AT after the 90 day blanking period was 86.4% (95% CI: 84.3%-88.3%) in patients with PAF and 70.9% (95% CI: 64.6%-76.4%) in patients with PsAF. Freedom from AF/AFL/AT in first-line PAF and PsAF was 90.0% (95% CI: 86.4%-92.7%) and 72.9% (95% CI: 58.6%-83.0%) at 12 months, respectively.
conclusionsThe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.